23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
23:57 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Windtree's Aerosurf misses in Phase IIb for RDS

Windtree Therapeutics Inc. (OTCQB:WINT) reported top-line data from a blinded, international Phase IIb trial in 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) showing that up to 2 repeat doses...
21:31 , Jun 16, 2017 |  BC Week In Review  |  Company News

Windtree grants Lee’s Asian rights to its KL4 surfactant products, including Aerosurf and Surfaxin

Windtree Therapeutics Inc. (OTCQB:WINT) granted Lee’s Pharmaceutical Holdings Ltd. (HKSE:950) exclusive rights to develop and commercialize KL4 surfactant products in China, Taiwan, Thailand and 13 other Asian territories based on Windtree’s KL4 surfactant and aerosolization...
19:52 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Windtree completes enrollment in Phase IIb of Aerosurf to treat RDS in premature infants

Windtree Therapeutics Inc. (OTCQB:WINT) completed enrollment of 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) in a Phase IIb trial of Aerosurf lucinactant. The trial is comparing up to 2...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Aerosurf lucinactant: Phase IIb started

Discovery Labs began a double-blind, international Phase IIb trial to compare up to 2 repeat doses of 25 or 50 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs. nCPAP alone in...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Completed Phase IIa enrollment

Discovery Labs completed enrollment of 32 premature infants of 29-34 weeks gestational age in an open-label Phase IIa trial comparing 60 and 90 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs....
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Financial News

Discovery Laboratories financial update

Discovery Laboratories Inc. (NASDAQ:DSCO), Warrington, Pa.   Business: Pulmonary   Date announced: 2015-07-22   Note: Discovery Labs raised $5.2 million through the sale of 8.7 million series A units at $0.60 to cover the overallotment...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Phase IIa data

Top-line data from an open-label, dose-escalation, U.S. Phase IIa trial in 48 premature infants receiving nasal continuous positive airway pressure (nCPAP) for RDS showed that single doses of 25, 50 and 75 mg/kg inhaled Aerosurf...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Financial News

Discovery Laboratories completes follow-on

Discovery Laboratories Inc. (NASDAQ:DSCO), Warrington, Pa.   Business: Pulmonary   Date completed: 2015-07-17   Type: Follow-on   Raised: $35 million   Units: 58.3 million   Price: $0.60 (unit)   Shares after offering: 104.2 million  ...